Limits...
Prevalence of renal impairment and use of nephrotoxic agents among patients with bone metastases from solid tumors in the United States.

Arellano J, Hernandez RK, Wade SW, Chen K, Pirolli M, Quach D, Quigley J, Liede A, Shahinian VB - Cancer Med (2015)

Bottom Line: The 5-year prevalence was 43% for RI and 71% for CKD among RI patients.Nearly half (46%) of CKD patients received IV BP in the 12 months following their confirming eGFR and 13% of these patients received at least one other nephrotoxic agent during that period.Whenever possible, treatments that are potentially less damaging for the kidney should be considered for patients with or predisposed to RI.

View Article: PubMed Central - PubMed

Affiliation: Amgen Inc., Thousand Oaks and South San Francisco, California.

No MeSH data available.


Related in: MedlinePlus

Patient selection.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4430264&req=5

fig01: Patient selection.

Mentions: A total of 24,512 patients with diagnoses of solid tumors and bone metastasis were identified. Among these patients, 11,809 (48%) met the inclusion criteria. The criterion for patients to have at least one serum creatinine value recorded during the study period eliminated ∼36% of the patients who met the criteria applied earlier in the selection process (Fig.1).


Prevalence of renal impairment and use of nephrotoxic agents among patients with bone metastases from solid tumors in the United States.

Arellano J, Hernandez RK, Wade SW, Chen K, Pirolli M, Quach D, Quigley J, Liede A, Shahinian VB - Cancer Med (2015)

Patient selection.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4430264&req=5

fig01: Patient selection.
Mentions: A total of 24,512 patients with diagnoses of solid tumors and bone metastasis were identified. Among these patients, 11,809 (48%) met the inclusion criteria. The criterion for patients to have at least one serum creatinine value recorded during the study period eliminated ∼36% of the patients who met the criteria applied earlier in the selection process (Fig.1).

Bottom Line: The 5-year prevalence was 43% for RI and 71% for CKD among RI patients.Nearly half (46%) of CKD patients received IV BP in the 12 months following their confirming eGFR and 13% of these patients received at least one other nephrotoxic agent during that period.Whenever possible, treatments that are potentially less damaging for the kidney should be considered for patients with or predisposed to RI.

View Article: PubMed Central - PubMed

Affiliation: Amgen Inc., Thousand Oaks and South San Francisco, California.

No MeSH data available.


Related in: MedlinePlus